vs
Side-by-side financial comparison of Millrose Properties, Inc. (MRP) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Millrose Properties, Inc. is the larger business by last-quarter revenue ($194.9M vs $158.6M, roughly 1.2× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 63.0%, a 8.1% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 135.7%).
Millrose Properties, Inc. is a U.S.-based real estate enterprise primarily focused on the acquisition, ownership, operation, and management of income-generating multi-family residential assets. Its core markets span the U.S. Mid-Atlantic and Southeast regions, and it also offers professional property management services to select third-party property owners.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
MRP vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $194.9M | $158.6M |
| Net Profit | $122.9M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 85.2% | 70.2% |
| Net Margin | 63.0% | 71.2% |
| Revenue YoY | 135.7% | 3661.1% |
| Net Profit YoY | 208.7% | 528.0% |
| EPS (diluted) | $0.74 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $194.9M | — | ||
| Q4 25 | $189.5M | — | ||
| Q3 25 | $179.3M | — | ||
| Q2 25 | $149.0M | — | ||
| Q1 25 | $82.7M | $158.6M | ||
| Q4 24 | — | $22.6M | ||
| Q2 23 | — | $-2.5M |
| Q1 26 | $122.9M | — | ||
| Q4 25 | $122.2M | — | ||
| Q3 25 | $105.1M | — | ||
| Q2 25 | $112.8M | — | ||
| Q1 25 | $39.8M | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q2 23 | — | $-30.7M |
| Q1 26 | 85.2% | — | ||
| Q4 25 | 84.8% | — | ||
| Q3 25 | 85.3% | — | ||
| Q2 25 | 85.1% | — | ||
| Q1 25 | 55.2% | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q2 23 | — | 1340.7% |
| Q1 26 | 63.0% | — | ||
| Q4 25 | 64.5% | — | ||
| Q3 25 | 58.6% | — | ||
| Q2 25 | 75.7% | — | ||
| Q1 25 | 48.1% | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q2 23 | — | 1235.6% |
| Q1 26 | $0.74 | — | ||
| Q4 25 | $0.74 | — | ||
| Q3 25 | $0.63 | — | ||
| Q2 25 | $0.68 | — | ||
| Q1 25 | $0.39 | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q2 23 | — | $-0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9B | $350.1M |
| Total Assets | $9.6B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.0M | — | ||
| Q3 25 | $242.6M | — | ||
| Q2 25 | $66.6M | — | ||
| Q1 25 | $89.5M | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q2 23 | — | $192.1M |
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $5.9B | — | ||
| Q1 25 | $5.9B | $350.1M | ||
| Q4 24 | — | $229.0M | ||
| Q2 23 | — | $190.2M |
| Q1 26 | $9.6B | — | ||
| Q4 25 | $9.3B | — | ||
| Q3 25 | $9.0B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.2B | $406.9M | ||
| Q4 24 | — | $271.6M | ||
| Q2 23 | — | $256.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | — | ||
| Q3 25 | $123.1M | — | ||
| Q2 25 | $109.1M | — | ||
| Q1 25 | $21.3M | $131.8M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-21.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-22.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q2 23 | — | 912.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q2 23 | — | -33.8% |
| Q1 26 | — | — | ||
| Q4 25 | 30.05× | — | ||
| Q3 25 | 1.17× | — | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 0.53× | 1.17× | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRP
| Option fee revenues | $185.3M | 95% |
| Development loan income | $9.6M | 5% |
STOK
Segment breakdown not available.
